Danielle Brill
Stock Analyst at Truist Financial
(4.72)
# 707
Out of 4,598 analysts
386
Total ratings
55%
Success rate
14.7%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Rated: Buy | $200 → $213 | $166.23 | +28.14% | 24 | Aug 3, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintained: Buy | n/a | $220.33 | - | 16 | Jul 31, 2026 | |
| BIIB Biogen | Reiterated: Buy | $235 | $201.82 | +16.44% | 19 | Jul 31, 2026 | |
| WVE Wave Life Sciences | Maintained: Buy | $15 | $5.74 | +161.32% | 3 | Jul 31, 2026 | |
| IRON Disc Medicine | Reiterated: Buy | $83 | $76.31 | +8.77% | 19 | Jul 31, 2026 | |
| ARGX argenx SE | Maintained: Buy | $1,030 | $830.79 | +23.98% | 33 | Jul 30, 2026 | |
| INSM Insmed | Maintained: Buy | n/a | $98.45 | - | 9 | Jul 17, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $560 | $470.72 | +18.97% | 8 | Jul 13, 2026 | |
| DNTH Dianthus Therapeutics | Maintained: Buy | n/a | $106.02 | - | 8 | Jun 15, 2026 | |
| PRAX Praxis Precision Medicines | Rated: Buy | $715 → $616 | $305.51 | +101.63% | 2 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $11.81 | - | 4 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $81 | $134.11 | -39.60% | 4 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $23 → $30 | $38.51 | -22.10% | 14 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $140.78 | - | 12 | May 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56 | $40.79 | +37.29% | 2 | May 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $43 | $6.42 | +569.78% | 6 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $27.33 | - | 4 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $27.92 | +114.90% | 11 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $102 | $79.96 | +27.56% | 14 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $25 → $29 | $35.57 | -18.47% | 19 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $9.16 | $44.06 | n/a | 23 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $9.96 | n/a | 3 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $25.61 | n/a | 19 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $79 | $60.00 | n/a | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $150 | $15.88 | n/a | 36 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $68.12 | n/a | 21 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $30.54 | n/a | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $52 → $50 | $62.26 | n/a | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $23.15 | n/a | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $6.76 | n/a | 19 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 → $10 | $4.49 | n/a | 5 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $13.40 | n/a | 1 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $45 | $10.11 | n/a | 2 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $49.53 | n/a | 10 | Feb 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $125 | $211.04 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 → $5 | $14.87 | n/a | 5 | Nov 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $131.15 | n/a | 1 | Jul 26, 2016 |
Neurocrine Biosciences
Aug 3, 2026
Rated: Buy
Price Target: $200 → $213
Current: $166.23
Upside: +28.14%
Alnylam Pharmaceuticals
Jul 31, 2026
Maintained: Buy
Price Target: n/a
Current: $220.33
Upside: -
Biogen
Jul 31, 2026
Reiterated: Buy
Price Target: $235
Current: $201.82
Upside: +16.44%
Wave Life Sciences
Jul 31, 2026
Maintained: Buy
Price Target: $15
Current: $5.74
Upside: +161.32%
Disc Medicine
Jul 31, 2026
Reiterated: Buy
Price Target: $83
Current: $76.31
Upside: +8.77%
argenx SE
Jul 30, 2026
Maintained: Buy
Price Target: $1,030
Current: $830.79
Upside: +23.98%
Insmed
Jul 17, 2026
Maintained: Buy
Price Target: n/a
Current: $98.45
Upside: -
Vertex Pharmaceuticals
Jul 13, 2026
Maintained: Buy
Price Target: $560
Current: $470.72
Upside: +18.97%
Dianthus Therapeutics
Jun 15, 2026
Maintained: Buy
Price Target: n/a
Current: $106.02
Upside: -
Praxis Precision Medicines
Jun 2, 2026
Rated: Buy
Price Target: $715 → $616
Current: $305.51
Upside: +101.63%
Jun 2, 2026
Maintained: Buy
Price Target: n/a
Current: $11.81
Upside: -
May 28, 2026
Rated: Hold
Price Target: $81
Current: $134.11
Upside: -39.60%
May 22, 2026
Maintained: Hold
Price Target: $23 → $30
Current: $38.51
Upside: -22.10%
May 21, 2026
Maintained: Buy
Price Target: n/a
Current: $140.78
Upside: -
May 19, 2026
Maintained: Buy
Price Target: $56
Current: $40.79
Upside: +37.29%
May 14, 2026
Maintained: Buy
Price Target: $43
Current: $6.42
Upside: +569.78%
May 14, 2026
Maintained: Buy
Price Target: n/a
Current: $27.33
Upside: -
May 11, 2026
Maintained: Buy
Price Target: $60
Current: $27.92
Upside: +114.90%
May 11, 2026
Reiterated: Buy
Price Target: $102
Current: $79.96
Upside: +27.56%
May 8, 2026
Maintained: Hold
Price Target: $25 → $29
Current: $35.57
Upside: -18.47%
Dec 10, 2024
Maintained: Buy
Price Target: $20 → $9.16
Current: $44.06
Upside: n/a
Nov 18, 2024
Reiterated: Buy
Price Target: $18
Current: $9.96
Upside: n/a
Oct 10, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $25.61
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $79
Current: $60.00
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $150
Current: $15.88
Upside: n/a
Oct 10, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $68.12
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $51
Current: $30.54
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $52 → $50
Current: $62.26
Upside: n/a
Oct 10, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $23.15
Upside: n/a
Jun 26, 2023
Downgraded: Hold
Price Target: n/a
Current: $6.76
Upside: n/a
May 16, 2022
Maintained: Buy
Price Target: $24 → $10
Current: $4.49
Upside: n/a
Jun 30, 2021
Initiated Coverage: Hold
Price Target: n/a
Current: $13.40
Upside: n/a
May 27, 2020
Maintained: Buy
Price Target: $35 → $45
Current: $10.11
Upside: n/a
Feb 13, 2020
Maintained: Hold
Price Target: n/a
Current: $49.53
Upside: n/a
Dec 16, 2019
Reiterated: Buy
Price Target: $125
Current: $211.04
Upside: n/a
Nov 7, 2019
Maintained: Hold
Price Target: $6 → $5
Current: $14.87
Upside: n/a
Jul 26, 2016
Downgraded: Hold
Price Target: n/a
Current: $131.15
Upside: n/a